Cookie Einstellungen
Diese Webseite verwendet ausschließlich notwendige Cookies, die für die Funktion erforderlich sind. Marketing- und Statistik-Cookies kommen nicht zum Einsatz. Weitere Informationen finden Sie in unserer Datenschutzerklärung.
 Notwendig   Details einblenden
      OK      
Bitte logge Dich ein, um diese Funktion zu nutzen!
      OK      
x
Impact News +++ Scripps reports Q4 2025 financial results (GlobeNewswire EN) +++ SCRIPPS Aktie +3,04%

LARIMAR Aktie

 >LARIMAR Aktienkurs 
4.94 EUR    +57.3%    (TradegateBSX)
Ask: 5.15 EUR / 290 Stück
Bid: 4.92 EUR / 305 Stück
Tagesumsatz: 15950 Stück
Realtime Kurs von 7:30 bis 22 Uhr!
LARIMAR Aktie über LYNX handeln
>LARIMAR Performance
1 Woche: +24,2%
1 Monat: +2,3%
3 Monate: 0%
6 Monate: -3,6%
1 Jahr: +8,9%
laufendes Jahr: -6,5%
>LARIMAR Aktie
Name:  LARIMAR THERAP.I. DL-,001
Land:  USA
Sektor:  Gesundheit
ISIN/ Wkn:  US5171251003 / A2P5PP
Symbol/ Ticker:  ZA71 (Frankfurt)
Kürzel:  FRA:ZA71, ETR:ZA71, ZA71:GR
Index:  -
Webseite:  https://larimartx.com/
Profil:  Larimar Therapeutics Inc. is a biotechnology company dedicated to developing treatments for complex rare diseases. The company's primary focus is on addressing unmet medical needs, particularly in the..
>Volltext..
Marktkapitalisierung:  204.28 Mio. EUR
Unternehmenswert:  58.34 Mio. EUR
Umsatz:  -
EBITDA:  -118.43 Mio. EUR
Nettogewinn:  -112.11 Mio. EUR
Gewinn je Aktie:  -1.64 EUR
Schulden:  3.69 Mio. EUR
Liquide Mittel:  76.56 Mio. EUR
Operativer Cashflow:  -81.95 Mio. EUR
Bargeldquote:  3.89
Umsatzwachstum:  -
Gewinnwachstum:  -93.36%
Dividende je Aktie:  -
Dividendenrendite:  -
Dividendenschätzung:  -
Insiderhandel:  -
Suchwörter:  LARIMAR
Letzte Datenerhebung:  25.02.26
>LARIMAR Kennzahlen
Aktien/ Unternehmen:
Aktien: 85.59 Mio. St.
Frei handelbar: 54.33%
Leerverk. Aktien: -
Rückkaufquote: -27.16%
Mitarbeiter: 65
Umsatz/Mitarb.: -
Analysten:
Analystenrating: Strong buy
Kursziel: 354.97%
Bewertung:
KGV: -
KGV lG: -
KUV: -
KBV: 2.2
PEG-Ratio: -0.02
EV/EBITDA: -
Rentabilität:
Bruttomarge: -
Gewinnmarge: -
Operative Marge: -
Managementeffizenz:
Gesamtkaprendite: -64.96%
Eigenkaprendite: -78.24%
>LARIMAR Peer Group
Gesundheit
 
25.02.26 - 22:18
Larimar Therapeutics launches proposed $75 million public offering (SeekingAlpha)
 
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...
25.02.26 - 20:39
Laminar Therapeutics Stock Is Popping Today: What′s Going On? (Benzinga)
 
Larimar Therapeutics Inc (NASDAQ:LRMR) shares are soaring on Wednesday after multiple analysts reiterated their bullish outlook. Importance Rank:  1 read more...
24.02.26 - 15:48
FDA-Sonderstatus für Friedreich-Ataxie-Medikament beflügelt Larimar-Aktie (Investing.com DE)
 
Um den gesamten Artikel unter de.investing.com zu lesen, klicken Sie bitte auf die Überschrift...
24.02.26 - 14:00
Larimar surges on FDA breakthrough status for lead asset (SeekingAlpha)
 
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...
05.11.25 - 18:33
Larimar Therapeutics GAAP EPS of -$0.61 misses by $0.21 (SeekingAlpha)
 
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...
28.10.25 - 15:03
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Larimar Therapeutics, Inc. - LRMR (PR Newswire)
 
NEW YORK, Oct. 28, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Larimar Therapeutics, Inc. ("Larimar" or the "Company") (NASDAQ: LRMR). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The......
23.10.25 - 16:12
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Larimar Therapeutics, Inc. - LRMR (PR Newswire)
 
NEW YORK, Oct. 23, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Larimar Therapeutics, Inc. ("Larimar" or the "Company") (NASDAQ: LRMR). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The......
16.10.25 - 10:45
Larimar Therapeutics, Inc. Investigated for Securities Fraud Violations - Contact the DJS Law Group to Discuss Your Rights - LRMR (PR Newswire)
 
LOS ANGELES, Oct. 16, 2025 /PRNewswire/ -- The DJS Law Group announces that it is investigating claims on behalf of investors of Larimar Therapeutics, Inc. ("Larimar" or "the Company") (NASDAQ: LRMR) for violations of the securities laws. INVESTIGATION DETAILS: The investigation focuses......
16.10.25 - 10:42
LRMR Investors Have Opportunity to Join Larimar Therapeutics, Inc. Fraud Investigation with the Schall Law Firm (PR Newswire)
 
LOS ANGELES, Oct. 16, 2025 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Larimar Therapeutics, Inc. ("Larimar" or "the Company") (NASDAQ: LRMR) for violations of the securities laws.......
13.10.25 - 19:54
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Larimar Therapeutics, Inc. - LRMR (PR Newswire)
 
NEW YORK, Oct. 13, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Larimar Therapeutics, Inc. ("Larimar" or the "Company") (NASDAQ: LRMR). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The......
08.10.25 - 22:39
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Larimar Therapeutics, Inc. - LRMR (PR Newswire)
 
NEW YORK, Oct. 8, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Larimar Therapeutics, Inc. ("Larimar" or the "Company") (NASDAQ: LRMR). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The......
29.09.25 - 17:12
Anaphylaxie-Fälle in Studie: Aktie von Larimar Therapeutics bricht ein (Investing.com DE)
 
Um den gesamten Artikel unter de.investing.com zu lesen, klicken Sie bitte auf die Überschrift...
29.09.25 - 13:03
Larimar Therapeutics Announces Positive Data from Ongoing Long-term Open Label Study and Updates to Nomlabofusp Program for Friedreich′s Ataxia (GlobeNewswire EN)
 
BALA CYNWYD, Pa., Sept. 29, 2025 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (Larimar) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today announced positive 25 mg and 50 mg data from the ongoing long-term open label (OL) study evaluating daily subcutaneous injections of nomlabofusp self-administered or administered by a caregiver in participants with Friedreich's ataxia (FA), a rare, progressive, and systemic disease with neurologic deterioration. The Company also provided a nomlabofusp development program update....
28.09.25 - 23:03
Larimar Therapeutics Announces Conference Call on the Nomlabofusp Program for the Treatment of Friedreich′s Ataxia (GlobeNewswire EN)
 
Conference call and webcast on Monday, September 29, 2025 at 8:00 am EDT Conference call and webcast on Monday, September 29, 2025 at 8:00 am EDT...
14.08.25 - 14:00
Larimar Beats Q2 Loss Estimates (Fool)
 
Um den gesamten Artikel unter fool.com zu lesen, klicken Sie bitte auf die Überschrift...
14.08.25 - 13:30
Larimar Therapeutics GAAP EPS of -$0.41 beats by $0.07 (SeekingAlpha)
 
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...
14.08.25 - 13:03
Larimar Therapeutics Reports Second Quarter 2025 Financial Results (GlobeNewswire EN)
 
*Pro forma cash, cash equivalents, and marketable securities of $203.6 million reflects $138.5 million of cash, cash equivalents and marketable securities as of June 30, 2025 combined with the $65.1 million in net proceeds from the recently completed July 2025 public offering....
31.07.25 - 22:18
Larimar Therapeutics Announces Closing of Underwritten Public Offering of Common Stock and Exercise in Full of the Underwriters′ Option to Purchase Additional Shares (GlobeNewswire EN)
 
BALA CYNWYD, Pa., July 31, 2025 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (“Larimar”) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today announced the closing of its previously announced underwritten public offering of 21,562,500 shares of its common stock, which includes the exercise in full of the underwriters' option to purchase 2,812,500 additional shares, at the public offering price of $3.20 per share. The aggregate gross proceeds to Larimar from this offering, before deducting underwriting discounts and commissions and offering expenses, were $69.0 million....
30.07.25 - 06:12
Larimar Therapeutics prices $60M stock offering (SeekingAlpha)
 
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...
30.07.25 - 05:54
Larimar Therapeutics Announces Pricing of Underwritten Public Offering (GlobeNewswire EN)
 
BALA CYNWYD, Pa., July 29, 2025 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (“Larimar”) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today announced the pricing of its previously announced underwritten public offering of 18,750,000 shares of its common stock at a price to the public of $3.20 per share. The aggregate gross proceeds to Larimar from this offering are expected to be $60.0 million, before deducting underwriting discounts and commissions and other offering expenses. In addition, Larimar has granted the underwriters a 30-day option to purchase up to an additional 2,812,500 shares of its common stock at the public offering price, less underwriting discounts and commissions. All shares of common stock are being offered by Larimar. The offering is expected to close on or about July 31, 2025, subject to the satisfaction of customary closing conditions....
>Behalte deine Investments mit realtime Kursen & News im Blick. Finde neue spannende Aktien! Registriere Dich und werde Mitglied!
Zitat des Tages: Verstohlene Geschenke nimmt der Gottlose an, den Gang des Rechtes zu beugen. - Altes Testament: Spruch
Partner:    >TradegateBSX Börse | >Dukascopy | >TradingView | >Boersentreff- Partner

Börsentreff auf Facebook | Börsentreff auf X | Börsentreff auf Instagram

Copyright @ Boersentreff.de - Die Märkte im Blick!